Valeant Pharmaceuticals Under Fresh Scrutiny Over Drug Pricing – ValueWalk Premium
Valeant
15Oct2015

Valeant Pharmaceuticals Under Fresh Scrutiny Over Drug Pricing

Valeant Pharmaceuticals disclosed late Wednesday that it was subpoenaed by U.S. prosecutors seeking information on its pricing programs.

In early trading on Thursday, Valeant’s U.S.-listed shares were down 9% at $156.53.


Valeant under fire for increasing drug prices
Valeant Pharmaceuticals has received subpoenas from U.S. prosecutors seeking information on drug-pricing decisions. In a statement on Wednesday night, the . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.

Author

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

Related Posts

Songbird Asset Management: Not Looking For Katy Perry

13 May, 2021

Not Looking For Katy Perry by Christine Song, Songbird Asset Management With a last name like Song, I was destined to love the TV singing show, The Voice. Each week, one... Read More

Warren Buffett

Analysts Never Stop Wondering When Buffett Will ‘Lose His Touch’

13 May, 2021

As one of the greatest investors of all time, it’s inevitable that every time Berkshire Hathaway Inc. (NYSE:BRK.A) (NYSE:BRK.B) underperforms the market someone will ask if the Oracle of Omaha... Read More

Tales of the Greatest Investors: John Maynard Keynes Part I

13 May, 2021

John Maynard Keynes was an extraordinary person. The best English language term that we have to describe him would be a polymath. He was not merely an economist; he... Read More

DoubleLine Opportunistic Credit Fund

DoubleLine Opportunistic Credit Fund Webcast [Slides]

30 August, 2019

On July 23 2019 Jeffrey Gundlach, Chief Executive Officer of DoubleLine Capital, held an audio webcast discussing the closed end funds Opportunistic Credit Fund (DBL) and Income Solutions Fund... Read More

Evanston Capital Management Wants In On HFT / Market Making Strategies

13 May, 2021

Fund of fund hedge fund manager Adam Blitz isn’t likely surprised at the surge of hedge fund closures in 2014. In a Bloomberg Briefs interview, Blitz outlined his core... Read More

Invest

Rockefeller Endowment Chief Beats Harvard, Yale; Sees Turmoil Ahead

8 October, 2020

Amy Falls had a great year -- and that’s making her nervous. Q2 2020 hedge fund letters, conferences and more pasja1000 / Pixabay Falls, chief investment officer at Rockefeller University’s $2.3 billion... Read More

China’s $37 Trillion Problem

14 May, 2021

According to new data, china's shadow Banking is now a $37 trillion problem. The global economy is currently in the middle of a period of strength. Business optimism is strong,... Read More

Fannie Mae

Fannie Mae Depositions – Richard Bove Comments

13 May, 2021

Richard X. Bove, Vice President Equity Research at Rafferty Capital Markets, highlights the depositions of Fannie Mae provided to the court that could be made public. The stock is... Read More

Gold And Silver In 2019: Where Are Prices Heading?

20 December, 2018

It's been an interesting year for precious metals, and things are about to get even more interesting. Various macro factors have been pointing to an increase in gold prices... Read More

Khrom Capital Returns 30% While Holding 43% Cash Reserve [UPDATED]

3 November, 2013

Check out how this value hedge fund (Khrom Capital) is doing (and no this is not a one time feat, but more like an average year) presented without further... Read More

X
Saved Articles
X
TextTExtLInkTextTExtLInk